Curium Acquires Zevacor Molecular

Curative Inc. Acquires KorvaLabs, Inc.

May 19, 2020

Healthcare Services

Curative Inc. has acquired KorvaLabs, a CLIA-certified and DEA-licensed analytical laboratory based in San Dimas, California, formalizing a partnership that supported Curative's manufacture and processing of its oral fluid COVID-19 test. The acquisition strengthens Curative's testing capacity — to date the organizations processed 245,371 tests together and were processing roughly 14,000 tests per day — and secures in-house manufacturing and processing capabilities.

Zevra Therapeutics Acquires Acer Therapeutics

November 20, 2023

Pharmaceuticals

Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Novartis Acquires Mariana Oncology

May 2, 2024

Biotechnology

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.

Rocket Pharmaceuticals Acquires Renovacor

September 20, 2022

Biotechnology

Rocket Pharmaceuticals (NASDAQ: RCKT) will acquire Renovacor (NYSE: RCOR) in an all-stock transaction valued at approximately $53 million (implied $2.60 per Renovacor share). The acquisition strengthens Rocket's leadership in AAV-based cardiac gene therapy by adding Renovacor's REN-001 BAG3-targeted program and related capabilities to Rocket's clinical pipeline.

ZS Acquires Intomics A/S

May 4, 2022

Biotechnology

ZS, a global professional services firm, has acquired Copenhagen-based bioinformatics and systems biology company Intomics A/S. The 42-person team and Intomics' curated protein-protein interaction network and analytics capabilities will expand ZS's drug discovery, bioinformatics and R&D offerings to better serve pharmaceutical, biotech and research clients.